MedTrace Logo

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RD01 (Pegerythropoietin) in Healthy Chinese Volunteers

NCT03657238 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2020-03-16

No results posted yet for this study

Summary

A first-time in human study to investigate the safety, tolerability and pharmacokinetics of RD01 in healthy Chinese subjects

Conditions

  • Healthy

Interventions

DRUG

RD01

single S.C. dose of RD01 for subjects in test group

DRUG

Placebo

single S.C. dose of placebo for subjects in placebo group

Sponsors & Collaborators

  • Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-08
Primary Completion
2019-08-02
Completion
2019-08-02

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03657238 on ClinicalTrials.gov